While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely o ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being un ...

Have you looked into how Phibro Animal Health (PAHC) performed internationally during the quarter ending March 2024? Considering the widespread global presence of this maker of animal health products and nutritional supplements, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In today's increasingly interconnected global economy, a company's ability to tap into international markets can be a pivotal factor in shaping its overall fin ...

Financial Performance - Consolidated net sales for the quarter ended March 31, 2024, were $263.2 million, reflecting an increase of $17.6 million or a 7% increase over the same quarter one year ago [32] - Adjusted EBITDA increased by $2.3 million, with Animal Health improving by $2.3 million or 7% due to gross profit from increased sales, partially offset by higher SG&A [11][12] - Year-to-date revenue growth was 3%, with adjusted EBITDA growth of negative 3% [30] Segment Performance - The Animal Health segment posted $181.3 million in net sales for the quarter, an increase of $16.9 million or 10% compared to the same quarter last year [12] - Nutritional Specialties net sales declined by $4.8 million or 11%, primarily due to lower demand for microbial and dairy products [13] - Performance Products segment net sales were $17.7 million, reflecting a decrease of $0.7 million or 4%, driven by decreased demand for personal care product ingredients and industrial chemicals [66] Market Performance - Growth in Animal Health was driven by strong performance in Medicated Feed Additives (MFA) and vaccines, with MFA and other net sales growth of $15 million or 16% [35] - Vaccine net sales grew by $6.7 million, a 26% increase driven by product launches in Latin America and increased domestic demand [35] - The highest growth areas geographically were North America and South America [17] Company Strategy and Industry Competition - The company announced an agreement to purchase Zoetis medicated feed additive portfolio, which is expected to lead to strong earnings accretion and support investments in faster-growing segments [4][5] - The acquisition is anticipated to enhance and diversify Phibro's species and product offerings, maximizing opportunities related to the portfolio [27] - The company aims to continue investing in Companion Animal, Nutritional Specialties, and Vaccines as key focus areas post-acquisition [46] Management Commentary on Operating Environment and Future Outlook - Management expressed optimism about continued growth in the Animal Health business and improvements in Mineral Nutrition and Performance Products as demand rebounds [28][38] - The company affirmed its guidance for net sales, adjusted EBITDA, and adjusted diluted EPS, while updating GAAP net income and diluted EPS to reflect one-time costs related to the Zoetis acquisition [15][65] - Management highlighted the importance of maintaining dividends and refinancing debt to support the acquisition [57] Other Important Information - The company generated $40 million of positive free cash flow for the 12 months ended March 31, 2024, with $79 million of operating cash flow and $39 million in capital expenditures [14] - Cash and cash equivalents and short-term investments were $99 million at the end of the quarter [14] - The gross leverage ratio was 4.4 times, and the net leverage ratio was 3.5 times at the end of the third quarter [14] Q&A Session Summary Question: What drove the growth in the MFA business? - Strong growth in the Animal Health segment, particularly in Medicated Feed Additives and vaccines, with growth experienced in North America and South America [17] Question: Can you provide an update on the Companion Animal pipeline? - Progress continues, with the Zoetis MFA acquisition expected to enhance investment capabilities in Companion Animal [43] Question: What is the impact of the veterinary feed directives on market opportunities? - The Zoetis MFA business includes products not considered medically important for human medicine, allowing the company to serve customers with antibiotic-free options [47]

Phibro Animal Health Corporation Webcast and Conference Call May 9, 2024 U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Financial Results Fiscal Year 2024 Third Quarter Ended March 31, 2024 May 9, 2024 Important Information Cautionary Statement Regarding Forward-Looking Statements Non-GAAP Financial Measures We use non-GAAP financial measures, such as adjusted EBITDA and adjusted net income, to assess and analyze our operational results and trends and to make financ ...

Highlights for the three months ended March 31, 2024 (compared to the three months ended March 31, 2023) Exhibit 99.1 For Immediate Release Phibro Animal Health Corporation Reports Third Quarter Results, Updates Financial Guidance TEANECK, N.J., May 8, 2024 (Business Wire) – Phibro Animal Health Corporation (Nasdaq: PAHC) ("Phibro" or the "Company") today announced financial results for its third quarter ended March 31, 2024 and its updated financial guidance for the year ending June 30, 2024. We affirm our ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13-184 ...

Phibro Animal Health Corporation (NASDAQ:PAHC) Q2 2024 Earnings Conference Call February 8, 2024 9:00 AM ET Company Participants Richard Johnson - Chief Financial Officer Jack Bendheim - Chairman, President and Chief Executive Officer Daniel Bendheim - Executive Vice President, Corporate Strategy Glenn David - Incoming Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Mikaela Franceschina - Barclays Brian Wright - Roth MKM Operator Hello and thank you for standing by. My name ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36410 Phibro Animal Health Corporation (Exact name of registrant as specified in its charter) Delaware 13- ...

Phibro Animal Health Corporation (NASDAQ:PAHC) Q1 2024 Earnings Conference Call November 9, 2023 9:00 AM ET Company Participants Daniel M. Bendheim - EVP, Corporate Strategy Jack C. Bendheim - Chairman, President & CEO Richard G. Johnson - Interim CFO Conference Call Participants Unidentified Analyst - Barclays Michael Ryskin - Bank of America Securities Brian Wright - ROTH MKM Partners Linda Bolduc - Morgan Stanley Operator Hello, and thank you for standing by. My name is Regina, and I will be your confere ...